Expand / Collapse search
Watch TV
Menu

This material may not be published, broadcast, rewritten, or redistributed. ©2024 FOX News Network, LLC. All rights reserved. Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions. Legal Statement. Mutual Fund and ETF data provided by Refinitiv Lipper.

story

Stocks to Watch, Feb. 13: Agilent Tech., Cendant, W.R. Berkley Corp.

By MarketWatch
Published | Updated

SAN FRANCISCO – Among the companies whose shares are expected to see active trade in Monday's session are Agilent Technologies Inc., Cendant Corp. and W.R. Berkley Corp.

Agilent Technologies Inc. (A) is expected to report fiscal first-quarter earnings of 30 cents a share, according to analysts polled by Thomson First Call.

Arch Capital Group Ltd. (ACGL) is seen posing a fourth-quarter profit of 95 cents a share.

Bob Evans Farms Inc.'s (BOBE) fiscal third-quarter results are expected to show a per-share profit of 25 cents, according to two analysts.

Cendant Corp. (CD) is expected to post earnings of 23 cents a share in its fourth quarter.

Forward Air Corp. (FWRD) is seen reporting a fourth-quarter profit of 42 cents a share.

Lincoln National Corp.'s (LNC) fourth-quarter earnings are expected to be $1.08 a share.

Mercury General Corp. (MCY) is expected to report a per-share profit of $1.06 in its fourth quarter.

Perry Ellis International Inc. (PERY) is seen posting a fourth-quarter profit of 80 cents a share.

W.R. Berkley Corp.'s (BER) fourth-quarter results are expected to show a per-share profit of $1.04.

Watch List

Fortune Brands Inc. (FO) said it has agreed to buy SBR Inc., a maker of vinyl-framed windows, for about $630 million, in a move to expand its home-improvement business. See full story.

Biogen Idec Inc. (BIIB) Genentech Inc. (DNA) said the Food and Drug Administration has approved Rituxan for use in the first-line treatment of patients with diffuse large B-cell, CD20-positive, non-Hodgkin's lymphoma in combination with anthracycline-based chemotherapy regimens. Rituxan was discovered by Biogen Idec, and the company co-markets it along with Genentech. Rituxan had previously been approved as a single agent for use in relapsed or refractory, low-grade or follicular, CD20-positive, B-cell non-Hodgkin's lymphoma.

Max Re Capital Ltd. (MXRE) reported a fourth-quarter net loss of $11.4 million, or 20 cents a share. During the same period a year ago, the Bermuda-based reinsurer posted net earnings of $87.1 million, or $1.82 a share. The net operating loss was $7.9 million, or 13 cents a share, for the quarter. Last year, net operating earnings were $80.8 million, or $1.67 a share. Analysts surveyed by Thomson First Call had forecast fourth-quarter earnings of 9 cents a share. Total revenue fell 11% to $271.7 million from $304.5 million. Net written premiums totaled $188.8 million vs. $97.1 million.

Northwest Airlines' (NWACQ) pilots will begin voting Monday on whether to give the union's leadership the authority to set a strike at the bankrupt airline, the Air Line Pilots Association. See full story.

Pfizer Inc. (PFE) expects 2006 sales and adjusted earnings to be flat with 2005 results, the No. 1 drugmaker said, citing the continued loss of market exclusivity for several key products. See full story.

Visteon Corp. (VC) said it swung to a fourth-quarter profit of $1.3 billion on the back of gains from its massive restructuring deal with former parent Ford Motor Co., but results still came up short of analyst targets. See full story.